GE wins nuc med deal

Article

GE Medical Systems has signed an exclusive multiyear agreement to supply American Diagnostic Medicine (ADM) with more than 40 PET and hybrid PET/CT imaging systems. The agreement includes GE's Discovery LS and Discovery VI, as well as its Advance NXi PET

GE Medical Systems has signed an exclusive multiyear agreement to supply American Diagnostic Medicine (ADM) with more than 40 PET and hybrid PET/CT imaging systems. The agreement includes GE's Discovery LS and Discovery VI, as well as its Advance NXi PET system. ADM has placed an initial order for six GE Discovery VI fused imaging systems, which will be installed in healthcare facilities in California, Florida, Illinois, and Texas. Privately held ADM runs hospital and healthcare facilities serving more than 100 healthcare organizations in the U.S. and worldwide. Imaging services include CT, MRI, and nuclear medicine.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.